Leflunomide

58 interactions 87 cited references

Also sold as: Arava Arava®

About Leflunomide

Leflunomide is used alone or in combination with other medications to treat rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function). Leflunomide is in a class of medications called disease-modifying antirheumatic drugs (DMARDs). It works by decreasing in… Read the full Leflunomide drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Teriflunomide Baricitinib Acyclovir Letermovir Injection Methotrexate Injection Adenovirus Vaccine Type 4, Live

1 Contraindicated 52 Major 5 Moderate

All (58) Contraindicated (1) Major (52) Moderate (5)

Major

Leflunomide Simvastatin Flolipid Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Acyclovir Avaclyr Increased exposure of OAT3 substrate Details Leflunomide Acyclovir Injection Avaclyr Increased exposure of OAT3 substrate Details Leflunomide Acyclovir Ophthalmic Avaclyr Increased exposure of OAT3 substrate Details Leflunomide Acyclovir Topical Zovirax Increased exposure of OAT3 substrate Details Leflunomide Azathioprine Azasan An increased risk of hepatotoxicity Details Leflunomide Atorvastatin Atorvaliq Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Baricitinib Olumiant Increased exposure of OAT3 substrate Details Leflunomide Cefaclor Ceclor® Increased exposure of OAT3 substrate Details Leflunomide Furosemide Injection Disal Increased exposure of OAT3 substrate Details Leflunomide Irinotecan Camptosar Increased exposure of BCRP substrate Details Leflunomide Irinotecan Injection Camptosar Increased exposure of BCRP substrate Details Leflunomide Adenovirus Vaccine Type 4, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details Leflunomide Adenovirus Vaccine Type 7, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details Leflunomide Bosentan Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Ciprofloxacin Increased exposure of OAT3 substrate Details Leflunomide Dabrafenib Tafinlar Increased exposure of CYP2C8 substrate Details Leflunomide Dasabuvir Increased exposure of CYP2C8 substrate Details Leflunomide Dengue Tetravalent Vaccine, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details Leflunomide Elagolix Orilissa Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Enzalutamide Xtandi Increased exposure of CYP2C8 substrate Details Leflunomide Furosemide Disal Increased exposure of OAT3 substrate Details Leflunomide Glyburide DiaBeta® Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Grazoprevir Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Influenza Virus Vaccine, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details Leflunomide Letermovir Prevymis Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Levoketoconazole Recorlev Increased risk of serious hepatotoxicity and drug-induced liver injury Details Leflunomide Measles Virus Vaccine, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details Leflunomide Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Leflunomide Methotrexate Jylamvo Increased exposure of methotrexate and increased risk of hepatotoxicity and bone marrow toxicity Details Leflunomide Montelukast Singulair Increased exposure of CYP2C8 substrate Details Leflunomide Mumps Virus Vaccine, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details Leflunomide Paclitaxel Abraxane Increased exposure of CYP2C8 substrate Details Leflunomide Pexidartinib Turalio Hepatotoxicity Details Leflunomide Pitavastatin Livalo Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Poliovirus Vaccine, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details Leflunomide Repaglinide Prandin® Increased repaglinide exposure Details Leflunomide Revefenacin Yupelri Increased exposure of OATP1B1/1B3 substrate Details Leflunomide Rosuvastatin Crestor Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Leflunomide Rotavirus Vaccine, Live An increased risk of secondary transmission of infection by the live vaccine and reduced effectiveness of immunization Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.